Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.48
(
0.32%
)
Bitcoin
68,698.36
(
1.27%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 11/11/2013 4:23:07 PM

Monday, November 11, 2013 4:23:07 PM

Post# of 257269
(KIN)—Former OXGN CEO, Richard Chin is the CEO of Kindred Biosciences, a drug company for pets that seeks to IPO:

http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/11/cats-dogs-horses-pets-medicine-kindred.html

Since its inception in late September 2012 until the end of June, Kindred has rung up a half-million dollars in research and development costs and has lost $738,986 overall. It had cash, equivalents and short-term investments of $3.1 million as of June 30.

When Chin was at OXGN, I thought he was a pretty good BS artist.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today